U.S. License Holder:
ADC Therapeutics SA
Date of License:
April-23-2021
Last Update:
Sep-30-2024
FDA-Approved Indications
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.